Oxford Biomedica Logo
Scientist microscope

Press releases 2005

Date Headline
12/12/05 Oxford BioMedica Announces Result of Extraordinary General Meeting
22/11/05 Oxford BioMedica Receives Notice of Patent Allowance Extending Trovax® Protection in the United States
16/11/05 Oxford BioMedica Commences Second Phase II Trial with Trovax® in Renal Cell Carcinoma
16/11/05 Oxford BioMedica Announces Underwritten Institutional Placing and Open Offer and Investment by Sigma-Aldrich to Raise £30.1 Million
10/11/05 Oxford BioMedica's Innurex® Nerve Regeneration Programme Highlighted During Briefing for £30 Million Link Programme
02/11/05 Oxford BioMedica Announces Progress with Registration Plan and Partnership Discussions for Trovax, and Proposed Institutional Placing and Open Offer for £20-£30 Million Alongside $5 Million Investment by Sigma-Aldrich
24/10/05 Oxford BioMedica Clarifies Trovax® Strategy
24/10/05 Oxford BioMedica Signs LentVector® Licensing Agreement with Fortune 500 Biopharmaceutical Company
20/10/05 Oxford BioMedica and Sigma-Aldrich Enter Strategic Alliance for Commercialisation of LentiVector® Technology
19/10/05 Oxford BioMedica Announces Presentation by Wyeth Pharmaceuticals of Preclinical Efficacy Data with Antibody-Targeted Therapy for Cancer
18/10/05 Oxford BioMedica Announces Presentation by Clinician of Phase II Results with MetXia® in Pancreatic Cancer
17/10/05 Oxford BioMedica Presents Encouraging Final Phase II Results with TroVax® in Colorectal Cancer at the International Colorectal Cancer Congress
06/10/05 Oxford BioMedica Announces Encouraging Preliminary Phase II Results with TroVax® in Renal Cell Carcinoma
03/10/05 Oxford BioMedica Announces Appointment of Evolution Securities as Sole Broker
20/09/05 Oxford BioMedica Plc Interim Results for the Six Months Ended 30 June 2005
07/09/05 Oxford BioMedica Announces Appointment of Chief Medical Officer
05/09/05 Notice of Interim Results for the Six Months Ended 30 June 2005
01/08/05 Oxford BioMedica Successfully Completes Stage One of the Phase II Trial with MetXia® in Pancreatic Cancer
25/07/05 Oxford BioMedica is Awarded Grant for MoNuDin® from the Motor Neurone Disease Association
04/07/05 Oxford BioMedica is Granted Key LentiVector® Patents in China
17/06/05 Oxford BioMedica to Chair Gene and RNAi Delivery Panel at the BIO 2005 Annual International Convention
06/06/05 Oxford BioMedica Signs LentiVector® Licensing Agreement with Pfizer
03/06/05 Oxford BioMedica, Viragen and the Roslin Institute Report Achievement of Avian Transgenic Milestone
03/06/05 Oxford BioMedica Presents Encouraging Innurex® Preclinical Efficacy Data in Spinal Cord Injury
16/05/05 Oxford BioMedica Presents Updated and Encouraging TroVax® Phase II Results in Colorectal Cancer at the 2005 ASCO Annual Meeting
12/05/05 Oxford BioMedica to Present New TroVax® Data from Phase II Trials in Colorectal Cancer at the 2005 ASCO Annual Meeting on 15 May
10/05/05 Oxford BioMedica Annual General Meeting 2005
09/05/05 Oxford BioMedica Receives European Patent for TroVax® Covering 5T4 Tumour Antigen-Targeted Immunotherapy
05/05/05 Oxford BioMedica Presents Encouraging Preclinical Efficacy Data with Retinostat® in Age-Related Macular Degeneration
29/03/05 Oxford BioMedica Receives Notice of Allowance for US LentiVector® Patent
29/03/05 Oxford BioMedica Notification of Annual General Meeting
21/03/05 Oxford BioMedica Announces Preliminary Results for the Year Ended 31 December 2004
14/03/05 Oxford BioMedica Demonstrates that Its LentiVector® Technology Is the System of Choice for RNAi Applications
10/03/05 Oxford BioMedica to Present at SG Cowen Health Care Conference
04/03/05 Oxford BioMedica Announces Board Appointment
04/03/05 Oxford BioMedica: Notice of FY2004 Preliminary Results
02/03/05 Oxford BioMedica Announces Encouraging Results from Three Phase II Trials of TroVax® in Patients with Colorectal Cancer
17/02/05 Oxford BioMedica and Viragen Report Progress in Avian Transgenics Biomanufacturing
07/02/05 Termination of Discussions
01/02/05 Oxford BioMedica Signs LentiVector® Licensing Agreement
19/01/05 Response to Share Price Movement
05/01/05 Oxford BioMedica Signs LentiVector® Licensing Agreement with Biogen Idec